[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunosuppressive-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunosuppressive-therapy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100620938","kidney-transplant-immunosuppressive-therapy-adherence-trial-kite-100620938",false,"NCT07364123","Kidney Transplant Immunosuppressive Therapy Adherence Trial (KITE)","Education and Telephone Counseling to Improve Adherence to Immunosuppressive Medication in Kidney Transplant Recipients: A Randomized Controlled Trial","KITE","Inclusion Criteria:\n\n* Adult kidney transplant recipients aged 18 years or older\n* At least 1 month post-kidney transplantation\n* Able to provide informed consent\n* Cognitively intact and oriented to person, place, and time\n* Able to communicate via telephone\n* Voluntarily willing to participate in the study\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Severe cognitive impairment preventing participation\n* Inability to communicate effectively (hearing or speech limitations without support)\n* Patients who do not meet the post-transplant time threshold (less than 1 month)\n* Patients unwilling or unable to participate in follow-up sessions","ALL","18 Years","70 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled interventional study aims to evaluate the effect of structured education and telephone counseling on immunosuppressive medication adherence among kidney transplant recipients. Poor adherence to immunosuppressive therapy after kidney transplantation is a major risk factor for acute rejection, graft loss, and increased morbidity. Education and behavioral support interventions delivered by nurses may improve medication understanding, adherence behaviors, and self-management skills.\n\nIn this trial, 60 participants will be randomly assigned to either an intervention group receiving individualized education, an immunosuppressive medication adherence booklet, and scheduled telephone counseling sessions, or a control group receiving routine clinical care. Adherence will be assessed using the Immunosuppressive Medication Adherence Scale and biological monitoring through tacrolimus level variability over 8 weeks. Additional outcomes include changes in medication knowledge scores based on pre-test and post-test assessments.\n\nThe study will contribute evidence regarding whether nurse-led telephone counseling and structured education can enhance adherence, improve clinical follow-up, and support long-term graft success in kidney transplant patients.",[28,29,30,31],"Kidney Transplantation","Medication Non-Adherence","Immunosuppressive Therapy","Renal Transplant Recipients",[33,34,35,36,37,38],"Kidney Transplant","Immunosuppressive Medication","Medication Adherence","Telephone Counseling","Patient Education","Tacrolimus Levels","NOT_YET_RECRUITING","2026-01-26",{"date":42,"type":43},"2026-01-28","ACTUAL",{"date":45,"type":22},"2026-01-05",{"date":47,"type":22},"2026-08-15",{"name":49,"class":50},"University of Gaziantep","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100569553","phase-2-reduced-dose-of-cyclophosphamide-combined-with-standard-immunosuppressive-therapy-to-treat-severe-aplastic-anemia-100569553","NCT06695741","Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia","Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy as Front-line Therapy in Patients With Severe Aplastic Anemia","hypo-CASH","Inclusion Criteria:\n\n* Subject has a diagnosis of naïve severe or very severe aplastic anemia\n* Male or female age ≥ 12 years\n* Unwilling or unable to receive allogeneic hematopoietic stem cell transplantation.\n* ECOG performance status ≤2\n* Willing and able to comply with the requirements for this study and written informed consent.\n\nExclusion Criteria:\n\n* Previously received immunosuppressive therapy \\> 4 weeks\n* Previously treated with TPO-RA \\> 4 weeks\n* Have an allergy or intolerance to anti-lymphocyte globulin, cyclosporine, herombopag or cyclophosphamide.\n* Uncontrolled fungal, bacterial, or viral infection. Hepatitis-associated aplastic anemia is allowed; hepatitis B or C infection is permitted unless it causes severe liver failure.\n* Tested positive for HIV or syphilis\n* Presence of severe liver, kidney, or heart failure, or other life-threatening comorbidities.\n* History of radiotherapy and chemotherapy for malignant solid tumors in recent 5 years\n* Combined with other serious disorders\n* Pregnant or breast-feeding patients\n* Patients considered to be ineligible for the study by the investigator for reasons other than the above.","12 Years",{"count":62,"type":22},75,[64],"PHASE2","This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of anti-lymphocyte globulin plus herombopag in combination with the reduced dose of cyclophosphamide (hypo-CASH) for severe aplastic anemia.",[67,68,30],"Severe Aplastic Anemia","Cyclophosphamide Reduced-dose","RECRUITING","2024-11-16",{"date":72,"type":43},"2024-11-19",{"date":74,"type":43},"2024-11-01",{"date":76,"type":22},"2027-06-30",{"name":78,"class":50},"Institute of Hematology & Blood Diseases Hospital, China"]